Compound 1817
Identifiers
- Canonical SMILES:
CCOc1cc(cc(c1)-c1c(C)noc1C)C(O)=O
- IUPAC name:
3-(3,5-dimethyl-1,2-oxazol-4-yl)-5-ethoxybenzoic acid
- InChi:
InChI=1S/C14H15NO4/c1-4-18-12-6-10(5-11(7-12)14(16)17)13-8(2)15-19-9(13)3/h5-7H,4H2,1-3H3,(H,16,17)
- InChiKey:
GAMMHRRBGXCHRX-UHFFFAOYSA-N
External links
![]() 53308655 |
![]() CHEMBL1828984 |
KRG |
External search
![]() |
![]() |
![]() |
![]() |
![]() |
Bibliography (1)
Pharmacological data
Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|
3 | 0 | 0 | 1 |
Targets
PPI family | Best activity | Diseases | MMoA |
---|---|---|---|
Bromodomain / Histone | 4.55 | breast cancer | Inhibition |
Physicochemical filters
Descriptor | Lipinski's RO5 | Veber | Pfizer's 3/75 | |
---|---|---|---|---|
Compliance | ||||
MW | 261.10 g/mol | |||
HBA | 5 | |||
HBD | 1 | |||
HBA + HBD | 6 | |||
AlogP | 2.17 | |||
TPSA | 75.39 | |||
RB | 4 |
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources | Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|---|
1 | 3 | 0 | 0 | 1 |
Pharmacological data
Bibliography | Name | Target | Competition | Assay type | Assay name | Cell line | Activity type | Activity |
---|---|---|---|---|---|---|---|---|
10.1021/jm200640v | 4b | CBP Q92793 |
H4 P62805 |
Biochemical assay | alphascreen BRD4 | pIC50 (half maximal inhibitory concentration, -log10) | 4.29 | |
10.1021/jm200640v | 4b | CBP Q92793 |
H4 P62805 |
Biochemical assay | alphascreen BRD2 | pIC50 (half maximal inhibitory concentration, -log10) | 4.55 | |
10.1021/jm200640v | 4b | CBP Q92793 |
H4 P62805 |
Biochemical assay | alphascreen CREBBP | pIC50 (half maximal inhibitory concentration, -log10) | 4.49 |
Cytotoxicity data
Bibliography | Name | Assay name | Cell line | Compound concentration (μM) | Toxicity |
---|---|---|---|---|---|
10.1021/jm200640v | 4b | MTT assay | HeLa | 10.000 | no |
Ta | Structure | Name | Drugbank ID |
---|---|---|---|
0.5000 | Valdecoxib | DB00580 | |
0.4677 | 5-(3-{3-[3-HYDROXY-2-(METHOXYCARBONYL)PHENOXY]PROPENYL}PHENYL)-4-(HYDROXYMETHYL)ISOXAZOLE-3-CARBOXYLIC ACID | DB08001 | |
0.4670 | 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE | DB06964 | |
0.4433 | Alobresib | DB14970 | |
0.4390 | Parecoxib | DB08439 | |
0.4272 | AUY922 | DB11881 | |
0.4249 | PX-102 | DB15416 | |
0.4238 | 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide | DB06961 | |
0.4185 | 5-(2-Fluoro-5-{(1E)-3-[3-hydroxy-2-(methoxycarbonyl)phenoxy]-1-propen-1-yl}phenyl)-1,2-oxazole-3-carboxylic acid | DB02014 | |
0.3933 | 2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[2-METHYL-4-ISOXAZOLYL]-PHENOL | DB08715 | |
0.3760 | Diflunisal | DB00861 | |
0.3708 | 2,6-DIMETHYL-1-(3-[3-METHYL-5-ISOXAZOLYL]-PROPANYL)-4-[4-METHYL-2H-TETRAZOL-2-YL]-PHENOL | DB08714 | |
0.3684 | Dipyrocetyl | DB13839 | |
0.3654 | 3-phenyl-5-(1H-pyrazol-3-yl)isoxazole | DB07613 | |
0.3651 | 3-(heptyloxy)benzoic acid | DB07355 |